# A Study to Evaluate the Effect of XY0206 on the QTc Interval in Chinese Healthy Participants

> **NCT07162116** · PHASE1 · RECRUITING · sponsor: **Shijiazhuang Yiling Pharmaceutical Co. Ltd** · enrollment: 45 (estimated)

## Conditions studied

- Acute Myeloid Leukemia With FLT3/ITD Mutation

## Interventions

- **DRUG:** XY0206
- **DRUG:** Moxifloxacin (400 mg)
- **OTHER:** XY0206 Placebo

## Key facts

- **NCT ID:** NCT07162116
- **Lead sponsor:** Shijiazhuang Yiling Pharmaceutical Co. Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-06
- **Primary completion:** 2025-12-01
- **Final completion:** 2026-05
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2025-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07162116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07162116, "A Study to Evaluate the Effect of XY0206 on the QTc Interval in Chinese Healthy Participants". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07162116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*